Literature DB >> 15761615

Changes in NAD/ADP-ribose metabolism in rectal cancer.

L Yalcintepe1, L Turker-Sener, A Sener, G Yetkin, D Tiryaki, E Bermek.   

Abstract

The extent of ADP-ribosylation in rectal cancer was compared to that of the corresponding normal rectal tissue. Twenty rectal tissue fragments were collected during surgery from patients diagnosed as having rectal cancer on the basis of pathology results. The levels of ADP-ribosylation in rectum cancer tissue samples (95.9 +/- 22.1 nmol/ml) was significantly higher than in normal tissues (11.4 +/- 4 nmol/ml). The level of NAD+ glycohydrolase and ADP-ribosyl cyclase activities in rectal cancer and normal tissue samples were measured. Cancer tissues had significantly higher NAD+ glycohydrolase and ADP-ribosyl cyclase activities than the control tissues (43.3 +/- 9.1 vs 29.2 +/- 5.2 and 6.2 +/- 1.6 vs 1.6 +/- 0.4 nmol mg(-1) min(-1)). Approximately 75% of the NAD+ concentration was consumed as substrate in rectal cancer, with changes in NAD+/ADP-ribose metabolism being observed. When [14C]-ADP-ribosylated tissue samples were subjected to SDS-PAGE, autoradiographic analysis revealed that several proteins were ADP-ribosylated in rectum tissue. Notably, the radiolabeling of a 113-kDa protein was remarkably greater than that in control tissues. Poly(ADP)-ribosylation of the 113-kDa protein in rectum cancer tissues might be enhanced with its proliferative activity, and poly(ADP)-ribosylation of the same protein in rectum cancer patients might be an indicator of tumor diagnosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15761615     DOI: 10.1590/s0100-879x2005000300006

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  8 in total

Review 1.  Trial watch - inhibiting PARP enzymes for anticancer therapy.

Authors:  Antonella Sistigu; Gwenola Manic; Florine Obrist; Ilio Vitale
Journal:  Mol Cell Oncol       Date:  2015-06-10

2.  Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types.

Authors:  Valeria Ossovskaya; Ingrid Chou Koo; Eric P Kaldjian; Christopher Alvares; Barry M Sherman
Journal:  Genes Cancer       Date:  2010-08

Review 3.  Pleiotropic role of PARP1: an overview.

Authors:  Vikas Kumar; Anurag Kumar; Khursheed Ul Islam Mir; Vandana Yadav; Shyam Singh Chauhan
Journal:  3 Biotech       Date:  2021-12-04       Impact factor: 2.406

4.  The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors.

Authors:  Mark Watson; Anne Roulston; Laurent Bélec; Xavier Billot; Richard Marcellus; Dominique Bédard; Cynthia Bernier; Stéphane Branchaud; Helen Chan; Kenza Dairi; Karine Gilbert; Daniel Goulet; Michel-Olivier Gratton; Henady Isakau; Anne Jang; Abdelkrim Khadir; Elizabeth Koch; Manon Lavoie; Michael Lawless; Mai Nguyen; Denis Paquette; Emilie Turcotte; Alvin Berger; Matthew Mitchell; Gordon C Shore; Pierre Beauparlant
Journal:  Mol Cell Biol       Date:  2009-08-24       Impact factor: 4.272

5.  Clinical significance of serum ADP-ribosylation and NAD glycohydrolase activity in patients with colorectal cancer.

Authors:  Başak Varol; Özlem Coşkun; Senem Karabulut; Kürşat Rahmi Serin; Oktar Asoğlu; Işıl Albeniz; Faruk Taş; Rüstem Nurten
Journal:  Tumour Biol       Date:  2014-02-18

6.  Inhibition of poly(ADP-ribose) polymerase 1 protects against acute myeloid leukemia by suppressing the myeloproliferative leukemia virus oncogene.

Authors:  Lingbo Wang; Weili Cai; Wei Zhang; Xueying Chen; Wenqian Dong; Dongqi Tang; Yun Zhang; Chunyan Ji; Mingxiang Zhang
Journal:  Oncotarget       Date:  2015-09-29

Review 7.  microRNAs Biogenesis, Functions and Role in Tumor Angiogenesis.

Authors:  Tiziana Annese; Roberto Tamma; Michelina De Giorgis; Domenico Ribatti
Journal:  Front Oncol       Date:  2020-11-27       Impact factor: 6.244

8.  A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT.

Authors:  Marine Barraud; Jonathan Garnier; Celine Loncle; Odile Gayet; Charlotte Lequeue; Sophie Vasseur; Benjamin Bian; Pauline Duconseil; Marine Gilabert; Martin Bigonnet; Aurélie Maignan; Vincent Moutardier; Stephane Garcia; Olivier Turrini; Jean-Robert Delpero; Marc Giovannini; Philippe Grandval; Mohamed Gasmi; Mehdi Ouaissi; Veronique Secq; Flora Poizat; Nicolas Guibert; Juan Iovanna; Nelson Dusetti
Journal:  Oncotarget       Date:  2016-08-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.